April 3rd 2024
This alters the course of developer Eisai's regulatory submission plans for lecanemab in the treatment of early Alzheimer disease.
The Science, Ethics, and Art of Disclosing a Dementia Diagnosis
How can you communicate the diagnosis in a way that relieves suffering and helps patients and their caregivers prepare for the future?
Read More